

METHODS IN MOLECULAR BIOLOGY™

Series Editor
John M. Walker
School of Life Sciences
University of Hertfordshire
Hatfield, Hertfordshire, AL10 9AB, UK

For further volumes:
<http://www.springer.com/series/7651>

Rational Drug Design

Methods and Protocols

Edited by

Yi Zheng

*Division of Experimental Hematology and Cancer Biology,
Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA*

Editor

Yi Zheng

Division of Experimental Hematology and Cancer Biology

Cincinnati Children's Hospital Medical Center

University of Cincinnati

Cincinnati, OH, USA

ISSN 1064-3745

ISSN 1940-6029 (electronic)

ISBN 978-1-62703-007-6

ISBN 978-1-62703-008-3 (eBook)

DOI 10.1007/978-1-62703-008-3

Springer New York Heidelberg Dordrecht London

Library of Congress Control Number: 2012943829

© Springer Science+Business Media New York 2012

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Humana Press is a brand of Springer

Springer is part of Springer Science+Business Media (www.springer.com)

Preface

Tremendous progress made in the past three decades of molecular biology studies of the cell signaling network has accumulated vast resources and knowledge that are ripe for harvesting for translational and therapeutic development. It is now clear that the traditional pharmaceutical Research & Development model may not be sustainable as evidenced by the recent flagging productivity in the pharmaceutical industry. New technological innovations in research of lead design, discovery, optimization, and validation, initiated by original ideas and concepts, may help mitigate the situation in the long run.

This volume of MiMM is aimed at offering some selected examples of novel methodologies involved in the dynamic and ever-changing field of rational drug design. The readers of this methodology reference book may adopt and modify the protocols and methods described in this volume in their efforts to translate unique bench-side ideas into discovering new leads of novel or established molecular targets in human diseases.

The areas covered in this volume include the following:

1. Virtual screening of chemical hits
2. Rational lead discovery by high-throughput screening
3. Combinatorial and fragment-based lead generation
4. Peptide-based drug discovery
5. Specificity and resistance
6. Effective delivery by RNA-based approach and nanotechnology
7. Animal models of lead validation

Structure-based virtual screening has emerged as an important tool in our quest to access novel drug-like compounds. There are a wide range of comparable and contrasting methodologies available in screening structural databases for hit identification. In Chap. 1 and several subsequent chapters, a strategy and several case studies utilizing the available virtual screening methods to identify hits and leads for small GTPases, phosphatases, or wnt pathway targets are presented. In addition to the traditional enzymatic targeting sites, such as the ATP-binding kinase domain or phosphatase domain, recent understanding of the structure–function relationship of many signaling proteins has allowed clever design of small molecule or peptidomimic inhibitors or activators against allosteric sites of the targets that significantly increase the specificity and efficacy. Examples of these also are discussed in the following chapters.

Complementary to the structure-based hit identification effort, mechanism-based screening approaches have proved fruitful leading to new leads of specific kinases and other enzymatic substrates. Examples in the successful application of yeast two-hybrid system, peptide aptamers, and peptide ligands are illustrated.

With the success of targeted therapy, development of drug resistance in disease cells has become an inevitable side effect. Recent progress in the drug discovery studies tackling the mechanism of drug resistance and applying rational designed second generation drugs to

overcome target expression/mutation changes for several kinases pioneers this future direction of rational drug design. This area of studies is represented by the identification, characterization, and rational design of new inhibitors in BCR-ABL targeted therapy.

Finally, a recent example of designing antisense microRNA and an example of delivering membrane-impermeable molecules into cells by nanotechnology, which can expand potential therapeutic options of rational designed drugs, are presented.

Overall, these complementary approaches to identify and validate hits specifically targeting a biologically implicated target, to overcome ensuing drug resistance and specificity issues, and to improve delivery efficiency to the target cells should be useful for the readers to appreciate the fast pace in rational drug design that may benefit future drug discovery effort.

Cincinnati, OH, USA

Yi Zheng, Ph.D.

Contents

<i>Preface</i>	<i>v</i>
<i>Contributors</i>	<i>ix</i>
1 On Setting Up and Assessing Docking Simulations for Virtual Screening. <i>Jacek Biesiada, Aleksey Porollo, and Jaroslaw Meller</i>	1
2 Virtual Ligand Screening Combined with NMR to Identify Dvl PDZ Domain Inhibitors Targeting the Wnt Signaling <i>Jufang Shan and Jie J. Zheng</i>	17
3 Rational Design of Rho GTPase-Targeting Inhibitors <i>Xun Shang and Yi Zheng</i>	29
4 Rational Design of Peptide Ligands Against a Glycolipid by NMR Studies. <i>Wenyong Tong, Tara Sprules, Kalle Gehring, and H. Uri Saragovi</i>	39
5 A Combinatorial Strategy for the Acquisition of Potent and Specific Protein Tyrosine Phosphatase Inhibitors <i>Sheng Zhang, Lan Chen, David S. Lawrence, and Zhong-Yin Zhang</i>	53
6 Identification of Allosteric Inhibitors of p21-Activated Kinase <i>Julien Viaud and Jeffrey R. Peterson</i>	67
7 Using a Modified Yeast Two-Hybrid System to Screen for Chemical GEF Inhibitors. <i>Anne Blangy and Philippe Fort</i>	81
8 Random Mutagenesis of Peptide Aptamers as an Optimization Strategy for Inhibitor Screening <i>Nathalie Bouquier, Sylvie Fromont, Anne Debant, and Susanne Schmidt</i>	97
9 A Screening Strategy for Trapping the Inactive Conformer of a Dimeric Enzyme with a Small Molecule Inhibitor. <i>Charles S. Craik and Tina Shahian</i>	119
10 Use of a Fluorescent ATP Analog to Probe the Allosteric Conformational Change in the Active Site of the Protein Kinase PDK1 <i>Valerie Hindie, Laura A. Lopez-Garcia, and Ricardo M. Biondi</i>	133
11 Affinity Purification of Protein Kinases that Adopt a Specific Inactive Conformation <i>Pratistha Ranjitkar and Dustin J. Maly</i>	143
12 Determination of the Kinetics and Thermodynamics of Ligand Binding to a Specific Inactive Conformation in Protein Kinases <i>Sanjay B. Hari, Pratistha Ranjitkar, and Dustin J. Maly</i>	153
13 Purification and Specific Assays for Measuring APE-1 Endonuclease Activity <i>Adrian Esqueda, Mohammed Z. Mohammed, Srinivasan Madhusudan, and Nouri Neamati</i>	161

14	An In Vitro Screening to Identify Drug-Resistant Mutations for Target-Directed Chemotherapeutic Agents	175
	<i>Mohammad Azam</i>	
15	Utilizing AntagomiR (Antisense microRNA) to Knock Down microRNA in Murine Bone Marrow Cells	185
	<i>Chinavenmeni S. Velu and H. Leighton Grimes</i>	
16	Synthesis, Conjugation, and Labeling of Multifunctional pRNA Nanoparticles for Specific Delivery of siRNA, Drugs, and Other Therapeutics to Target Cells	197
	<i>Peixuan Guo, Yi Shu, Daniel Binzel, and Mathieu Cinier</i>	
17	Mouse Models for Tumor Metastasis	221
	<i>Shengyu Yang, J. Jillian Zhang, and Xin-Yun Huang</i>	
	<i>Index</i>	229

Contributors

- MOHAMMAD AZAM • *Divisions of Pathology, Hematology and Cancer Biology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, USA; Department of Medicine, University of Cincinnati, Cincinnati, OH, USA*
- JACEK BIESIADA • *Biomedical Informatics, Children's Hospital Research Foundation, Cincinnati, OH, USA; Division of Management and Informatics, Technical University of Silesia, Katowice, Poland*
- DANIEL BINZEL • *Nanobiomedical Center, University of Cincinnati, Cincinnati, OH, USA*
- RICARDO M. BIONDI • *Department of Internal Medicine I, Research Group PhosphoSites, Universitätsklinikum Frankfurt, Frankfurt, Germany*
- ANNE BLANGY • *Universités Montpellier2 & 1, Montpellier, France; CNRS, UMR5237, Montpellier, France*
- NATHALIE BOQUIER • *Centre de Recherche de Biochimie Macromoléculaire, CNRS-UMR 5237, Universités Montpellier I et II, Montpellier Cedex, France*
- LAN CHEN • *Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA*
- MATHIEU CINIER • *Nanobiomedical Center, University of Cincinnati, Cincinnati, OH, USA*
- CHARLES S. CRAIK • *Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA*
- ANNE DEBANT • *Centre de Recherche de Biochimie Macromoléculaire, CNRS-UMR 5237, Universités Montpellier I et II, Montpellier Cedex 5, France*
- ADRIAN ESQUEDA • *Laboratory of Molecular Oncology, School of Molecular Medical Sciences, University of Nottingham, Nottingham, UK*
- PHILIPPE FORT • *Universités Montpellier2 & 1, CRBM, Montpellier, France; CNRS, UMR5237, Montpellier, France*
- SYLVIE FROMONT • *Centre de Recherche de Biochimie Macromoléculaire, CNRS-UMR 5237, Universités Montpellier I et II, Montpellier Cedex 5, France*
- KALLE GEHRING • *Department of Biochemistry and the Cancer Center, McGill University, Montreal, QC, Canada; Quebec/Eastern Canada High Field NMR Facility, McGill University, Montreal, QC, Canada*
- H. LEIGHTON GRIMES • *Immunobiology Division, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA*
- PEIXUAN GUO • *Nanobiomedical Center, University of Cincinnati, Cincinnati, OH, USA*
- SANJAY B. HARI • *Department of Chemistry, University of Washington, Seattle, WA, USA*
- VALERIE HINDIE • *Department of Internal Medicine I, Research Group PhosphoSites, Universitätsklinikum Frankfurt, Frankfurt, Germany*

- XIN-YUN HUANG • *Department of Physiology, Cornell University Weill Medical College, New York, NY, USA*
- DAVID S. LAWRENCE • *Division of Medicinal Chemistry and Natural Products, Department of Chemistry, University of North Carolina, Chapel Hill, NC, USA*
- LAURA A. LOPEZ-GARCIA • *Department of Internal Medicine I, Research Group PhosphoSites, Universitätsklinikum Frankfurt, Frankfurt, Germany*
- SRINIVASAN MADHUSUDAN • *Laboratory of Molecular Oncology, School of Molecular Medical Sciences, University of Nottingham, Nottingham, UK*
- DUSTIN J. MALY • *Department of Chemistry, University of Washington, Seattle, WA, USA*
- JAROSLAW MELLER • *Biomedical Informatics, Children's Hospital Research Foundation, Cincinnati, OH, USA; Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, OH, USA; Department of Informatics, Nicholas Copernicus University, Torun, Poland*
- MOHAMMED Z. MOHAMMED • *Laboratory of Molecular Oncology, School of Molecular Medical Sciences, University of Nottingham, Nottingham, UK*
- NOURI NEAMATI • *Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, School of Pharmacy, Los Angeles, CA, USA*
- JEFFREY R. PETERSON • *Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA, USA*
- ALEKSEY POROLLO • *Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, OH, USA*
- PRATISTHA RANJITKAR • *Department of Chemistry, University of Washington, Seattle, WA, USA*
- H. URI SARAGOVI • *Lady Davis Institute-Jewish General Hospital, Montréal, QC, Canada; Departments of Pharmacology and Therapeutics, Oncology and the Cancer Center, McGill University, Montréal, QC, Canada*
- SUSANNE SCHMIDT • *Centre de Recherche de Biochimie Macromoléculaire, CNRS-UMR Universités Montpellier I et II, Montpellier Cedex, France*
- TINA SHAHIAN • *Graduate Group in Biochemistry and Molecular Biology, University of California, San Francisco, San Francisco, CA, USA*
- JUFANG SHAN • *Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN, USA*
- XUN SHANG • *Division of Experimental Hematology and Cancer Biology, Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA*
- YI SHU • *Nanobiomedical Center, University of Cincinnati, Cincinnati, OH, USA*
- TARA SPRULES • *Quebec/Eastern Canada High Field NMR Facility, McGill University, Montreal, QC, Canada*
- WENYONG TONG • *Lady Davis Institute-Jewish General Hospital, Montréal, QC, Canada; Departments of Pharmacology and Therapeutics, and the Cancer Center, McGill University, Montreal, QC, Canada*
- CHINAVENMENI S. VELU • *Immunobiology Division, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA*
- JULIEN VIAUD • *Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA, USA*

SHENGYU YANG • *Department of Physiology, Cornell University Weill Medical College, New York, USA; Department of Molecular Oncology, Moffitt Cancer Center, Tampa, FL, USA*

J. JILLIAN ZHANG • *Department of Physiology, Cornell University Weill Medical College, New York, NY, USA*

SHENG ZHANG • *Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA*

ZHONG-YIN ZHANG • *Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA*

JIE J. ZHENG • *Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN, USA*

YI ZHENG • *Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA*

